Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
Indian J Chest Dis Allied Sci 2006 Jul-Sep; 48(3):183-6IJ

Abstract

BACKGROUND

We carried out this study to determine the efficacy and safety of a regimen containing kanamycin, ethionamide, isoniazid, para-aminosalicylic acid (PAS) and cycloserine in the treatment of multidrug-resistant tuberculosis (MDR-TB).

METHODS

A prospective, uncontrolled study of 39 pulmonary tuberculosis patients, who had received adequate first-line antituberculosis treatment including supervised category II retreatment regimen, and were still sputum smear positive for acid-fast bacilli (AFB) in whom sputum culture revealed isolates of M. tuberculosis resistant to rifampicin and isoniazid with and without resistance to other antituberculosis drugs. They received kanamycin (initial 4-6 months), ethionamide, isoniazid, PAS and cycloserine for a minimum period of two years.

RESULTS

Out of 39 patients, 29 (74.3%) achieved sputum conversion within six months and remained so at the end of two years. Two (5.1%) patients died, six (20.6%) patients were lost to follow up, and two (5.1%) patients remained sputum smear-positive for AFB through out the period of study. Twenty-nine patients, declared cured, were followed for an average period of 16 months (3-48 months), during which two (6.9%) patients relapsed, four (13.8%) patients were lost to follow-up and remaining 23 remained sputum smear-negative. Eight (21.1%) patients developed major side effects which required stoppage/change of drugs.

CONCLUSION

In MDR-TB patients, regimen consisting of ethionamide, isoniazid, PAS and cycloserine and kanamycin appears to be effective and safe.

Authors+Show Affiliations

Department of Pulmonary Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India. rprasad2@sancharnet.inNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18610675

Citation

Prasad, R, et al. "Efficacy and Safety of Kanamycin, Ethionamide, PAS and Cycloserine in Multidrug-resistant Pulmonary Tuberculosis Patients." The Indian Journal of Chest Diseases & Allied Sciences, vol. 48, no. 3, 2006, pp. 183-6.
Prasad R, Verma SK, Sahai S, et al. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci. 2006;48(3):183-6.
Prasad, R., Verma, S. K., Sahai, S., Kumar, S., & Jain, A. (2006). Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. The Indian Journal of Chest Diseases & Allied Sciences, 48(3), pp. 183-6.
Prasad R, et al. Efficacy and Safety of Kanamycin, Ethionamide, PAS and Cycloserine in Multidrug-resistant Pulmonary Tuberculosis Patients. Indian J Chest Dis Allied Sci. 2006;48(3):183-6. PubMed PMID: 18610675.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. AU - Prasad,R, AU - Verma,S K, AU - Sahai,S, AU - Kumar,S, AU - Jain,A, PY - 2008/7/10/pubmed PY - 2008/8/13/medline PY - 2008/7/10/entrez SP - 183 EP - 6 JF - The Indian journal of chest diseases & allied sciences JO - Indian J Chest Dis Allied Sci VL - 48 IS - 3 N2 - BACKGROUND: We carried out this study to determine the efficacy and safety of a regimen containing kanamycin, ethionamide, isoniazid, para-aminosalicylic acid (PAS) and cycloserine in the treatment of multidrug-resistant tuberculosis (MDR-TB). METHODS: A prospective, uncontrolled study of 39 pulmonary tuberculosis patients, who had received adequate first-line antituberculosis treatment including supervised category II retreatment regimen, and were still sputum smear positive for acid-fast bacilli (AFB) in whom sputum culture revealed isolates of M. tuberculosis resistant to rifampicin and isoniazid with and without resistance to other antituberculosis drugs. They received kanamycin (initial 4-6 months), ethionamide, isoniazid, PAS and cycloserine for a minimum period of two years. RESULTS: Out of 39 patients, 29 (74.3%) achieved sputum conversion within six months and remained so at the end of two years. Two (5.1%) patients died, six (20.6%) patients were lost to follow up, and two (5.1%) patients remained sputum smear-positive for AFB through out the period of study. Twenty-nine patients, declared cured, were followed for an average period of 16 months (3-48 months), during which two (6.9%) patients relapsed, four (13.8%) patients were lost to follow-up and remaining 23 remained sputum smear-negative. Eight (21.1%) patients developed major side effects which required stoppage/change of drugs. CONCLUSION: In MDR-TB patients, regimen consisting of ethionamide, isoniazid, PAS and cycloserine and kanamycin appears to be effective and safe. SN - 0377-9343 UR - https://www.unboundmedicine.com/medline/citation/18610675/Efficacy_and_safety_of_kanamycin_ethionamide_PAS_and_cycloserine_in_multidrug_resistant_pulmonary_tuberculosis_patients_ L2 - http://www.diseaseinfosearch.org/result/7252 DB - PRIME DP - Unbound Medicine ER -